Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers

Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling

(2011) L. Buitrago et al.   BLOOD

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors

(2011) D. Dicker   DIABETES CARE

Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective

(2011) Nicholaos Kakouros et al.   International Journal of Endocrinology

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control

(2010) P. Anagnostis et al.   DIABETES OBESITY & METABOLISM

Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]

(2010) Sachiko Hattori   ENDOCRINE JOURNAL

A key role for dense granule secretion in potentiation of the Ca2+ signal arising from store-operated calcium entry in human platelets

(2009) Alan G.S. Harper et al.   CELL CALCIUM

Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis

(2009) P. D. Reaven et al.   DIABETES

Antiplatelet Activity of Epigallocatechin Gallate Is Mediated by the Inhibition of PLCγ2 Phosphorylation, Elevation of PGD2 Production, and Maintaining Calcium-ATPase Activity

(2009) Yong-Ri Jin et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein

(2008) M A D Ferreira et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY